PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33727814-4 2021 These radiation-resistant cells exhibit upregulated human copper transporter 1 (hCtr1), which also transports cisplatin. Cisplatin 110-119 solute carrier family 31 member 1 Homo sapiens 58-78 33727814-4 2021 These radiation-resistant cells exhibit upregulated human copper transporter 1 (hCtr1), which also transports cisplatin. Cisplatin 110-119 solute carrier family 31 member 1 Homo sapiens 80-85 32207235-0 2020 PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1. Cisplatin 48-57 solute carrier family 31 member 1 Homo sapiens 113-120 33404748-1 2021 Copper transporter 1 (CTR1) is a transport protein involved in copper and cisplatin uptake. Cisplatin 74-83 solute carrier family 31 member 1 Homo sapiens 0-20 33404748-1 2021 Copper transporter 1 (CTR1) is a transport protein involved in copper and cisplatin uptake. Cisplatin 74-83 solute carrier family 31 member 1 Homo sapiens 22-26 33404748-2 2021 The visualization of cellular CTR1 migration and its redistribution is highly important in copper/cisplatin exposure/transport. Cisplatin 98-107 solute carrier family 31 member 1 Homo sapiens 30-34 33404748-6 2021 This dual-mode imaging strategy facilitates visualization of CTR1 migration and meanwhile provides information of CTR1 redistribution in HepG2 cells by uptake of divalent copper or cisplatin. Cisplatin 181-190 solute carrier family 31 member 1 Homo sapiens 114-118 32704405-1 2020 Human copper transporter 1 (hCtr1) is the main transporter of copper which has been involved as an essential cofactor in biological processes and mechanisms of action for cisplatin and its analogues. Cisplatin 171-180 solute carrier family 31 member 1 Homo sapiens 6-26 32704405-1 2020 Human copper transporter 1 (hCtr1) is the main transporter of copper which has been involved as an essential cofactor in biological processes and mechanisms of action for cisplatin and its analogues. Cisplatin 171-180 solute carrier family 31 member 1 Homo sapiens 28-33 31779287-4 2019 Expression of cisplatin transporters Ctr1 and MRP2 was analyzed. Cisplatin 14-23 solute carrier family 31 member 1 Homo sapiens 37-41 30959888-12 2019 CTR1 KO cells, but not DMT1 KO, demonstrated reduced sensitivity to cisplatin and silver ions, the agents that enter the cell through CTR1. Cisplatin 68-77 solute carrier family 31 member 1 Homo sapiens 0-4 32665841-4 2019 The expression of the copper transporter 1 (CTR1) protein in cells directly corresponds with cDDP uptake and its cellular toxicity. Cisplatin 93-97 solute carrier family 31 member 1 Homo sapiens 44-48 31050072-0 2019 Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1. Cisplatin 49-58 solute carrier family 31 member 1 Homo sapiens 92-112 31050072-5 2019 Immunohistochemistry staining showed that the expression level of the mature form CTR1, the major influx transporter of cisplatin, was low in osteosarcoma tissue. Cisplatin 120-129 solute carrier family 31 member 1 Homo sapiens 82-86 31050072-6 2019 However, oleandrin with or without cisplatin significantly increased the expression and membrane localization of the mature CTR1. Cisplatin 35-44 solute carrier family 31 member 1 Homo sapiens 124-128 31050072-7 2019 Furthermore, CTR1 knockdown reversed the synergistic effect and decreased cisplatin uptake. Cisplatin 74-83 solute carrier family 31 member 1 Homo sapiens 13-17 31050072-11 2019 The synergy results from the enhanced cisplatin uptake via oleandrin-mediated inhibition of proteasome activity and subsequent blockage of the mature CTR1 degradation. Cisplatin 38-47 solute carrier family 31 member 1 Homo sapiens 150-154 30614075-0 2019 Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake. Cisplatin 66-75 solute carrier family 31 member 1 Homo sapiens 21-41 30614075-2 2019 Copper transporter 1 (CTR1), which contains one N-glycan on Asn15 , mediates cellular transport of cisplatin (cDDP), and plays an important role in the process of cDDP-resistance in EOC. Cisplatin 99-108 solute carrier family 31 member 1 Homo sapiens 0-20 30614075-2 2019 Copper transporter 1 (CTR1), which contains one N-glycan on Asn15 , mediates cellular transport of cisplatin (cDDP), and plays an important role in the process of cDDP-resistance in EOC. Cisplatin 99-108 solute carrier family 31 member 1 Homo sapiens 22-26 30614075-2 2019 Copper transporter 1 (CTR1), which contains one N-glycan on Asn15 , mediates cellular transport of cisplatin (cDDP), and plays an important role in the process of cDDP-resistance in EOC. Cisplatin 110-114 solute carrier family 31 member 1 Homo sapiens 0-20 30614075-2 2019 Copper transporter 1 (CTR1), which contains one N-glycan on Asn15 , mediates cellular transport of cisplatin (cDDP), and plays an important role in the process of cDDP-resistance in EOC. Cisplatin 110-114 solute carrier family 31 member 1 Homo sapiens 22-26 30614075-2 2019 Copper transporter 1 (CTR1), which contains one N-glycan on Asn15 , mediates cellular transport of cisplatin (cDDP), and plays an important role in the process of cDDP-resistance in EOC. Cisplatin 163-167 solute carrier family 31 member 1 Homo sapiens 0-20 30614075-2 2019 Copper transporter 1 (CTR1), which contains one N-glycan on Asn15 , mediates cellular transport of cisplatin (cDDP), and plays an important role in the process of cDDP-resistance in EOC. Cisplatin 163-167 solute carrier family 31 member 1 Homo sapiens 22-26 30614075-4 2019 The in vitro assays also indicate that core fucosylation of CTR1 was significantly upregulated in cDDP-resistant A2780CP cells compared to the cDDP-sensitive A2780S cells. Cisplatin 98-102 solute carrier family 31 member 1 Homo sapiens 60-64 30614075-4 2019 The in vitro assays also indicate that core fucosylation of CTR1 was significantly upregulated in cDDP-resistant A2780CP cells compared to the cDDP-sensitive A2780S cells. Cisplatin 143-147 solute carrier family 31 member 1 Homo sapiens 60-64 30614075-5 2019 Intriguingly, the hyper core fucosylation suppressed the CTR1-cDDP interactions and cDDP-uptake into A2780CP cells. Cisplatin 62-66 solute carrier family 31 member 1 Homo sapiens 57-61 30614075-9 2019 Our findings suggest that the core fucosylation of CTR1 plays an important role in the cellular cDDP-uptake and thus provide new strategies for improving the outcome of cDDP based chemotherapy of EOC. Cisplatin 96-100 solute carrier family 31 member 1 Homo sapiens 51-55 30614075-9 2019 Our findings suggest that the core fucosylation of CTR1 plays an important role in the cellular cDDP-uptake and thus provide new strategies for improving the outcome of cDDP based chemotherapy of EOC. Cisplatin 169-173 solute carrier family 31 member 1 Homo sapiens 51-55 30959888-12 2019 CTR1 KO cells, but not DMT1 KO, demonstrated reduced sensitivity to cisplatin and silver ions, the agents that enter the cell through CTR1. Cisplatin 68-77 solute carrier family 31 member 1 Homo sapiens 134-138 29954488-13 2018 The low levels of Ctr1 and high levels of ATP7B in MCF-7R caused G5-GA75 to allow the accumulation of cisplatin, which in turn increased the cytotoxicity. Cisplatin 102-111 solute carrier family 31 member 1 Homo sapiens 18-22 30195880-0 2018 Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop. Cisplatin 18-27 solute carrier family 31 member 1 Homo sapiens 93-97 30195880-3 2018 Copper transporter 1 (CTR1) on the plasma membrane of eukaryotic cells mediates both copper as well as anticancer drug cisplatin uptake. Cisplatin 119-128 solute carrier family 31 member 1 Homo sapiens 0-20 30195880-3 2018 Copper transporter 1 (CTR1) on the plasma membrane of eukaryotic cells mediates both copper as well as anticancer drug cisplatin uptake. Cisplatin 119-128 solute carrier family 31 member 1 Homo sapiens 22-26 30195880-4 2018 PURPOSE: This study aims to investigate whether curcumin enhances cisplatin sensitivity of human non-small cell lung cancer (NSCLC) through influencing Cu-Sp1-CTR1 regulatory loop. Cisplatin 66-75 solute carrier family 31 member 1 Homo sapiens 159-163 30195880-10 2018 Curcumin treatment enhances the binding of Sp1 to CTR1 and Sp1 promoters, thus induces CTR1 expression and chemosensitization to cisplatin treatment. Cisplatin 129-138 solute carrier family 31 member 1 Homo sapiens 50-54 30195880-12 2018 Moreover, the enhancement mediated by curcumin on cisplatin therapeutic efficacy in cultured human NSCLC cell lines (A549, H460, H1299) was dependent on CTR1. Cisplatin 50-59 solute carrier family 31 member 1 Homo sapiens 153-157 28516214-0 2017 Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. Cisplatin 16-25 solute carrier family 31 member 1 Homo sapiens 53-57 29152741-4 2018 The copper transporter 1 (CTR1) has been the focus of many recent studies because of its correlation with cisplatin (CDDP) resistance. Cisplatin 106-115 solute carrier family 31 member 1 Homo sapiens 4-24 29152741-4 2018 The copper transporter 1 (CTR1) has been the focus of many recent studies because of its correlation with cisplatin (CDDP) resistance. Cisplatin 106-115 solute carrier family 31 member 1 Homo sapiens 26-30 29152741-4 2018 The copper transporter 1 (CTR1) has been the focus of many recent studies because of its correlation with cisplatin (CDDP) resistance. Cisplatin 117-121 solute carrier family 31 member 1 Homo sapiens 4-24 29152741-4 2018 The copper transporter 1 (CTR1) has been the focus of many recent studies because of its correlation with cisplatin (CDDP) resistance. Cisplatin 117-121 solute carrier family 31 member 1 Homo sapiens 26-30 29479997-0 2018 Correlation of Expression Levels of Copper Transporter 1 andThymidylate Synthase with Treatment Outcomes in Patientswith Advanced Non-small Cell Lung Cancer Treated withS-1/Carboplatin Doublet Chemotherapy Background: Copper transporter 1 (CTR1) is a critical determinant of the uptake and cytotoxic effect of the platinumdrugs carboplatin and cisplatin. Cisplatin 344-353 solute carrier family 31 member 1 Homo sapiens 36-80 29479997-0 2018 Correlation of Expression Levels of Copper Transporter 1 andThymidylate Synthase with Treatment Outcomes in Patientswith Advanced Non-small Cell Lung Cancer Treated withS-1/Carboplatin Doublet Chemotherapy Background: Copper transporter 1 (CTR1) is a critical determinant of the uptake and cytotoxic effect of the platinumdrugs carboplatin and cisplatin. Cisplatin 344-353 solute carrier family 31 member 1 Homo sapiens 218-238 31938179-2 2018 Human copper transporter 1 (hCTR1) was proven as crucial regulator for cellular platinum uptake in cancer cells and improving effect of cisplatin treatment. Cisplatin 136-145 solute carrier family 31 member 1 Homo sapiens 6-26 31938179-2 2018 Human copper transporter 1 (hCTR1) was proven as crucial regulator for cellular platinum uptake in cancer cells and improving effect of cisplatin treatment. Cisplatin 136-145 solute carrier family 31 member 1 Homo sapiens 28-33 31938179-6 2018 Overexpression of hCTR1 RNA was detected in 12 samples using RT-LAMP within 45 minutes reaction, which indicated positivity with cisplatin resistance. Cisplatin 129-138 solute carrier family 31 member 1 Homo sapiens 18-23 31938179-7 2018 This new technique is suggested to be alternative for rapid diagnosis of cisplatin sensitive patients whose hCTR1 is prevalent. Cisplatin 73-82 solute carrier family 31 member 1 Homo sapiens 108-113 28382507-8 2018 Extensive research has found that cisplatin entry into a cell is facilitated by a number of cellular transporters including human copper transport protein 1 (Ctr1) and the organic cation transporter 2 (OCT2) which are expressed on renal tubular cells. Cisplatin 34-43 solute carrier family 31 member 1 Homo sapiens 130-156 28382507-8 2018 Extensive research has found that cisplatin entry into a cell is facilitated by a number of cellular transporters including human copper transport protein 1 (Ctr1) and the organic cation transporter 2 (OCT2) which are expressed on renal tubular cells. Cisplatin 34-43 solute carrier family 31 member 1 Homo sapiens 158-162 29301278-0 2018 Theaflavin-3,3"-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells. Cisplatin 60-69 solute carrier family 31 member 1 Homo sapiens 88-108 29301278-7 2018 Treatment with TF3 decreased the glutathione (GSH) levels and upregulated the protein levels of the copper transporter 1 (CTR1) in both cells, which led to the enhanced sensitivity of both ovarian cancer cells to cisplatin. Cisplatin 213-222 solute carrier family 31 member 1 Homo sapiens 100-120 29301278-7 2018 Treatment with TF3 decreased the glutathione (GSH) levels and upregulated the protein levels of the copper transporter 1 (CTR1) in both cells, which led to the enhanced sensitivity of both ovarian cancer cells to cisplatin. Cisplatin 213-222 solute carrier family 31 member 1 Homo sapiens 122-126 29737086-0 2018 [Basic Research of the Adenovirus-mediated hCTR1 Transfection on the Treatment of Cisplatin Resistant Cervical Cancer]. Cisplatin 82-91 solute carrier family 31 member 1 Homo sapiens 43-48 29737086-5 2018 Recombinant adenovirus ad-hCTR1 was transfected into tumor by intratumoral injection and combined with cisplatin chemotherapy. Cisplatin 103-112 solute carrier family 31 member 1 Homo sapiens 26-31 29737086-8 2018 The cytotoxic IC50 value of cisplatin on C-33A/cis had been upgraded from (1.86+-0.08) to (8.11+-0.21) mumol/L,while the CTR1 was found decreased by Western blot assay. Cisplatin 28-37 solute carrier family 31 member 1 Homo sapiens 121-125 29737086-9 2018 Immunohistochemical analysis indicated that CTR1 expression was increased by intratumoral injection of adenovirus ad-hCTR1, and the tumor growth of C-33A/cis drug-resistant cervical carcinoma xenograft was inhibited by ad-hCTR1 transfection combined with cisplatin. Cisplatin 255-264 solute carrier family 31 member 1 Homo sapiens 44-48 29772714-2 2018 Drug importing, intracellular shuffling, and exporting-carried out by the high-affinity copper (Cu) transporter (hCtr1), Cu chaperone (Ato x1), and Cu exporters (ATP7A and ATP7B), respectively-cumulatively contribute to the chemosensitivity of Pt drugs including cisplatin and carboplatin, but not oxaliplatin. Cisplatin 263-272 solute carrier family 31 member 1 Homo sapiens 113-118 28516214-2 2017 While there is a clinical correlation between CTR1 levels and platinum efficacy, cellular studies have provided conflicting evidence relating to the relationship between cisplatin and CTR1. Cisplatin 170-179 solute carrier family 31 member 1 Homo sapiens 184-188 28516214-4 2017 While the accumulation of copper and platinum do not appear to compete with each other, we did observe that cisplatin perturbs CTR1 distribution within 10 min, a far shorter incubation time than commonly employed in cellular studies of cisplatin. Cisplatin 108-117 solute carrier family 31 member 1 Homo sapiens 127-131 28383086-2 2017 The copper transport protein, hCTR1, is proposed to facilitate the cellular uptake of cisplatin, whereas organic cation transport (OCT) is more important for oxaliplatin. Cisplatin 86-95 solute carrier family 31 member 1 Homo sapiens 30-35 28383086-3 2017 It has been reported that both N-terminal and C-terminal metal binding motifs of hCTR1 are highly reactive to cisplatin, which is the initial step of protein assisted cellular uptake of cisplatin. Cisplatin 110-119 solute carrier family 31 member 1 Homo sapiens 81-86 28383086-3 2017 It has been reported that both N-terminal and C-terminal metal binding motifs of hCTR1 are highly reactive to cisplatin, which is the initial step of protein assisted cellular uptake of cisplatin. Cisplatin 186-195 solute carrier family 31 member 1 Homo sapiens 81-86 28383086-9 2017 The different reactivity is consistent with the hypothesis that hCTR1 is more significant in the transport of cisplatin than that of oxaliplatin. Cisplatin 110-119 solute carrier family 31 member 1 Homo sapiens 64-69 27877224-3 2016 Recent studies have shown that the mammalian copper transporters CTR1, ATP7A and ATP7B are involved in cisplatin-resistance to some cancers. Cisplatin 103-112 solute carrier family 31 member 1 Homo sapiens 65-69 27980217-1 2017 Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation. Cisplatin 166-175 solute carrier family 31 member 1 Homo sapiens 0-20 27980217-1 2017 Copper transporter 1 (CTR1), copper transporter 2 (CTR2), copper-transporting p-type adenosine triphosphatase 1 and 2 (ATP7A and ATP7B) are key mediators of cellular cisplatin, carboplatin and oxaliplatin accumulation. Cisplatin 166-175 solute carrier family 31 member 1 Homo sapiens 22-26 27172866-1 2016 The human high-affinity copper transporter 1 (hCtr1) transports both Cu(I) and cisplatin (cDDP). Cisplatin 79-88 solute carrier family 31 member 1 Homo sapiens 46-51 27157188-0 2016 Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Cisplatin 81-90 solute carrier family 31 member 1 Homo sapiens 35-39 27172866-1 2016 The human high-affinity copper transporter 1 (hCtr1) transports both Cu(I) and cisplatin (cDDP). Cisplatin 90-94 solute carrier family 31 member 1 Homo sapiens 46-51 27172866-4 2016 hCtr1 expression is also upregulated by cDDP via upregulation of Sp1. Cisplatin 40-44 solute carrier family 31 member 1 Homo sapiens 0-5 26906901-10 2016 The uptake of Cisplatin was reduced by 30% in A2780 in which the copper transporter-1 (Ctr1) was silenced. Cisplatin 14-23 solute carrier family 31 member 1 Homo sapiens 65-85 27270317-0 2016 NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Cisplatin 47-56 solute carrier family 31 member 1 Homo sapiens 31-35 27270317-2 2016 Our previous study revealed that the green tea polyphenol, EGCG, induced cisplatin transporter CTR1 (copper transporter 1) and enhanced cisplatin sensitivity in ovarian cancer. Cisplatin 73-82 solute carrier family 31 member 1 Homo sapiens 95-99 27270317-2 2016 Our previous study revealed that the green tea polyphenol, EGCG, induced cisplatin transporter CTR1 (copper transporter 1) and enhanced cisplatin sensitivity in ovarian cancer. Cisplatin 73-82 solute carrier family 31 member 1 Homo sapiens 101-121 27112899-3 2016 Here we illustrate that cisplatin resistance in human ovarian cancer cells (A2780) correlates with a reduced expression of LRRC8A and copper transporter receptor 1 (CTR1), as well as a concomitant increased expression of copper-transporting P-type ATPases (ATP7A/ATP7B). Cisplatin 24-33 solute carrier family 31 member 1 Homo sapiens 165-169 26906901-10 2016 The uptake of Cisplatin was reduced by 30% in A2780 in which the copper transporter-1 (Ctr1) was silenced. Cisplatin 14-23 solute carrier family 31 member 1 Homo sapiens 87-91 26906901-13 2016 Moreover, our data demonstrated that the uptake of Cisplatin is partially dependent on Ctr1 transporter, while uptake of RJY6 is marginally dependent on Ctr1 and RJY13 is Ctr1-independent. Cisplatin 51-60 solute carrier family 31 member 1 Homo sapiens 87-91 26235215-1 2015 The human copper protein (hCTR1) is believed to facilitate the cellular uptake of cisplatin. Cisplatin 82-91 solute carrier family 31 member 1 Homo sapiens 26-31 26637863-1 2015 Copper transporter 1 (CTR1) represents an important determinant of cisplatin resistance. Cisplatin 67-76 solute carrier family 31 member 1 Homo sapiens 0-20 26637863-1 2015 Copper transporter 1 (CTR1) represents an important determinant of cisplatin resistance. Cisplatin 67-76 solute carrier family 31 member 1 Homo sapiens 22-26 26637863-2 2015 A series of 35 semi-substituted steroids were recently investigated on cisplatin-resistant CTR1-expressing A2780cis ovarian carcinoma cells as well as their parental sensitive counterparts regarding their cytotoxic and resistance-reversing features. Cisplatin 71-80 solute carrier family 31 member 1 Homo sapiens 91-95 26637863-6 2015 These steroids have the potential for further development as CTR1 inhibitors overcoming cisplatin resistance. Cisplatin 88-97 solute carrier family 31 member 1 Homo sapiens 61-65 26235215-2 2015 Cisplatin likely binds to the methionine (Met)-rich motifs located in the N-terminus of hCTR1, and ligand exchange would be essential if cisplatin has to pass through the hCTR1 channel. Cisplatin 0-9 solute carrier family 31 member 1 Homo sapiens 88-93 26235215-2 2015 Cisplatin likely binds to the methionine (Met)-rich motifs located in the N-terminus of hCTR1, and ligand exchange would be essential if cisplatin has to pass through the hCTR1 channel. Cisplatin 0-9 solute carrier family 31 member 1 Homo sapiens 171-176 26235215-2 2015 Cisplatin likely binds to the methionine (Met)-rich motifs located in the N-terminus of hCTR1, and ligand exchange would be essential if cisplatin has to pass through the hCTR1 channel. Cisplatin 137-146 solute carrier family 31 member 1 Homo sapiens 171-176 26121483-0 2015 Correction: EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. Cisplatin 26-35 solute carrier family 31 member 1 Homo sapiens 120-124 26121483-0 2015 Correction: EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. Cisplatin 91-100 solute carrier family 31 member 1 Homo sapiens 120-124 26004625-6 2015 Mechanism of copper-lowering agents in enhancing hCtr1-mediated cis-diamminedichloroplatinum (II) (cisplatin, cDDP) transport is reviewed. Cisplatin 64-92 solute carrier family 31 member 1 Homo sapiens 49-54 25927922-0 2015 EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. Cisplatin 14-23 solute carrier family 31 member 1 Homo sapiens 108-112 25927922-0 2015 EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. Cisplatin 79-88 solute carrier family 31 member 1 Homo sapiens 108-112 25927922-2 2015 CTR1 (copper transporter 1), a transmembrane solute carrier transporter, has previously been shown to increase the cellular uptake and sensitivity of cisplatin. Cisplatin 150-159 solute carrier family 31 member 1 Homo sapiens 0-4 25964760-5 2015 The copper transporter 1 seems to be of particular importance for cisplatin uptake in tumor cells, while the organic cation transporter (OCT) 2, due to its specific organ distribution, may play a major role in the development of undesired cisplatin side effects. Cisplatin 66-75 solute carrier family 31 member 1 Homo sapiens 4-24 25927922-2 2015 CTR1 (copper transporter 1), a transmembrane solute carrier transporter, has previously been shown to increase the cellular uptake and sensitivity of cisplatin. Cisplatin 150-159 solute carrier family 31 member 1 Homo sapiens 6-26 25927922-3 2015 It is hypothesized that increased CTR1 expression would enhance the sensitivity of cancer cells to cisplatin (cDDP). Cisplatin 99-108 solute carrier family 31 member 1 Homo sapiens 34-38 26004625-6 2015 Mechanism of copper-lowering agents in enhancing hCtr1-mediated cis-diamminedichloroplatinum (II) (cisplatin, cDDP) transport is reviewed. Cisplatin 99-108 solute carrier family 31 member 1 Homo sapiens 49-54 25594011-0 2014 Integrin alphaV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. Cisplatin 66-75 solute carrier family 31 member 1 Homo sapiens 127-131 25823781-1 2015 AIM: Assuming that genetic variants of the SLC22A2 and SLC31A1 transporter affect patients" susceptibility to cisplatin-induced ototoxicity, we compared the distribution of 11 SLC22A2 variants and the SLC31A1 variant rs10981694 between patients with and without cisplatin-induced ototoxicity. Cisplatin 110-119 solute carrier family 31 member 1 Homo sapiens 55-62 25091475-6 2014 To evaluate the cytotoxic effects induced by hCTR1 expression, the dose-dependent cell survival rate after treatment with cisplatin (Cis-diaminedichloroplatinum (II) [CDDP]) was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and trypan blue dye exclusion. Cisplatin 122-131 solute carrier family 31 member 1 Homo sapiens 45-50 25091475-6 2014 To evaluate the cytotoxic effects induced by hCTR1 expression, the dose-dependent cell survival rate after treatment with cisplatin (Cis-diaminedichloroplatinum (II) [CDDP]) was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and trypan blue dye exclusion. Cisplatin 133-160 solute carrier family 31 member 1 Homo sapiens 45-50 25091475-9 2014 MTT assay and trypan blue dye exclusion showed that the cell viability of MDA-MB-231-hCTR1 cells decreased more rapidly than that of MDA-MB-231 cells after treatment with CDDP for 96 or 72 h, respectively. Cisplatin 171-175 solute carrier family 31 member 1 Homo sapiens 85-90 24967972-0 2014 Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Cisplatin 39-48 solute carrier family 31 member 1 Homo sapiens 71-75 24967972-1 2014 The copper influx transporter CTR1 is also a major influx transporter for cisplatin (cDDP) in tumor cells. Cisplatin 74-83 solute carrier family 31 member 1 Homo sapiens 30-34 24967972-1 2014 The copper influx transporter CTR1 is also a major influx transporter for cisplatin (cDDP) in tumor cells. Cisplatin 85-89 solute carrier family 31 member 1 Homo sapiens 30-34 24447817-1 2014 Human copper transporter 1 (hCTR1) is the high-affinity copper influx transporter in mammalian cells that also mediates the influx of cisplatin. Cisplatin 134-143 solute carrier family 31 member 1 Homo sapiens 6-26 24447817-1 2014 Human copper transporter 1 (hCTR1) is the high-affinity copper influx transporter in mammalian cells that also mediates the influx of cisplatin. Cisplatin 134-143 solute carrier family 31 member 1 Homo sapiens 28-33 25594011-3 2014 In this study, we found that down-regulation of alphaV sensitized human M21 cells to cisplatin (cDDP) through up-regulation of the copper influx transporter CTR1. Cisplatin 85-94 solute carrier family 31 member 1 Homo sapiens 157-161 24403514-6 2014 We have also used sequenced combinations of platinum drugs and bortezomib (a proteasome inhibitor that prevents cisplatin-induced proteasomal degration of copper transporter CTR1) to enhance cellular platinum accumulation and the level of platinum-DNA binding especially in the resistant human ovarian tumour models. Cisplatin 112-121 solute carrier family 31 member 1 Homo sapiens 174-178 24522273-2 2014 CTR1 serves as an influx transporter for both Cu and cisplatin (cDDP). Cisplatin 53-62 solute carrier family 31 member 1 Homo sapiens 0-4 24522273-2 2014 CTR1 serves as an influx transporter for both Cu and cisplatin (cDDP). Cisplatin 64-68 solute carrier family 31 member 1 Homo sapiens 0-4 24132751-0 2014 Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. Cisplatin 73-82 solute carrier family 31 member 1 Homo sapiens 52-57 24132751-7 2014 Thus, regulation of hCtr1 expression by cisplatin is an integral part of the copper homeostasis regulation system. Cisplatin 40-49 solute carrier family 31 member 1 Homo sapiens 20-25 24132751-4 2014 It has been demonstrated that human high-affinity copper transporter 1 (hCtr1) is involved in transporting cisplatin into cells to elicit cytotoxic effects, although other mechanisms may exist. Cisplatin 107-116 solute carrier family 31 member 1 Homo sapiens 72-77 24132751-5 2014 In this communication, we demonstrate that cisplatin transcriptionally induces the expression of hCtr1 in time- and concentration-dependent manners. Cisplatin 43-52 solute carrier family 31 member 1 Homo sapiens 97-102 24132751-6 2014 Cisplatin functions as a competitor for hCtr1-mediated copper transport, resulting in reduced cellular copper levels and leading to upregulated expression of Sp1, which is a positive regulator for hCtr1 expression. Cisplatin 0-9 solute carrier family 31 member 1 Homo sapiens 40-45 24132751-6 2014 Cisplatin functions as a competitor for hCtr1-mediated copper transport, resulting in reduced cellular copper levels and leading to upregulated expression of Sp1, which is a positive regulator for hCtr1 expression. Cisplatin 0-9 solute carrier family 31 member 1 Homo sapiens 197-202 24122981-6 2013 The ubiquitously expressed Ctr1 seems to be involved in general cisplatin uptake in tumor and normal cells. Cisplatin 64-73 solute carrier family 31 member 1 Homo sapiens 27-31 23988033-4 2014 The copper (Cu) transport proteins Ctr1 and ATP7A/B have been implicated in cellular resistance of CisPt, possibly exporting the drug out of the cell. Cisplatin 99-104 solute carrier family 31 member 1 Homo sapiens 35-39 24209693-3 2013 Copper transporter 1 is involved in the transport of cisplatin into the cell, but is also down-regulated by the drug. Cisplatin 53-62 solute carrier family 31 member 1 Homo sapiens 0-20 24122978-3 2013 The human high-affinity copper (Cu) transporter-1 (hCtr1) can also transport Pt-based drugs including cisplatin (cDDP) and carboplatin. Cisplatin 102-111 solute carrier family 31 member 1 Homo sapiens 51-56 24167251-0 2013 Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-binding ecto-domain. Cisplatin 104-113 solute carrier family 31 member 1 Homo sapiens 57-61 24167251-7 2013 These studies identify a key regulatory mechanism for mammalian copper transport through Ctr2-dependent accumulation of a Ctr1 variant lacking the copper- and cisplatin-binding ecto-domain. Cisplatin 159-168 solute carrier family 31 member 1 Homo sapiens 122-126 24122981-3 2013 Several transporters are able to mediate the movement of cisplatin across the plasma membranes: Copper transporter-1 (Ctr1), copper transporter-2 (Ctr2), P-type copper-transporting ATPases ATP7A and ATP7B, organic cation transporter-2 (OCT2), and multidrug extrusion transporter-1 (MATE1). Cisplatin 57-66 solute carrier family 31 member 1 Homo sapiens 96-116 24122981-3 2013 Several transporters are able to mediate the movement of cisplatin across the plasma membranes: Copper transporter-1 (Ctr1), copper transporter-2 (Ctr2), P-type copper-transporting ATPases ATP7A and ATP7B, organic cation transporter-2 (OCT2), and multidrug extrusion transporter-1 (MATE1). Cisplatin 57-66 solute carrier family 31 member 1 Homo sapiens 118-122 24122981-5 2013 In the present review article, we focus on the role of Ctr1 and OCT2 for cellular uptake of cisplatin and on the possibilities to reduce cisplatin-associated toxicities decreasing cisplatin uptake mediated by these transporters. Cisplatin 92-101 solute carrier family 31 member 1 Homo sapiens 55-59 23642142-1 2013 Human copper transporter 1 (hCTR1) facilitates the cellular uptake of cisplatin, and the extracellular N-terminal domain has been proven to coordinate to platinum drugs. Cisplatin 70-79 solute carrier family 31 member 1 Homo sapiens 6-26 23879689-0 2013 A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment. Cisplatin 95-104 solute carrier family 31 member 1 Homo sapiens 34-38 23879689-3 2013 We hypothesised that hyperthermia increases cisplatin accumulation and efficacy by modulating function of copper transport protein 1 (Ctr1), a major regulator of cellular cisplatin uptake. Cisplatin 44-53 solute carrier family 31 member 1 Homo sapiens 106-132 23879689-3 2013 We hypothesised that hyperthermia increases cisplatin accumulation and efficacy by modulating function of copper transport protein 1 (Ctr1), a major regulator of cellular cisplatin uptake. Cisplatin 44-53 solute carrier family 31 member 1 Homo sapiens 134-138 23879689-3 2013 We hypothesised that hyperthermia increases cisplatin accumulation and efficacy by modulating function of copper transport protein 1 (Ctr1), a major regulator of cellular cisplatin uptake. Cisplatin 171-180 solute carrier family 31 member 1 Homo sapiens 106-132 23879689-3 2013 We hypothesised that hyperthermia increases cisplatin accumulation and efficacy by modulating function of copper transport protein 1 (Ctr1), a major regulator of cellular cisplatin uptake. Cisplatin 171-180 solute carrier family 31 member 1 Homo sapiens 134-138 23879689-4 2013 We examined the significance of Ctr1 in the synergistic interaction between hyperthermia and cisplatin. Cisplatin 93-102 solute carrier family 31 member 1 Homo sapiens 32-36 23879689-5 2013 We assessed the importance of cisplatin- and hyperthermia-induced Ctr1 multimerisation in sensitising cells to cisplatin cytotoxicity. Cisplatin 30-39 solute carrier family 31 member 1 Homo sapiens 66-70 23879689-5 2013 We assessed the importance of cisplatin- and hyperthermia-induced Ctr1 multimerisation in sensitising cells to cisplatin cytotoxicity. Cisplatin 111-120 solute carrier family 31 member 1 Homo sapiens 66-70 23879689-9 2013 RESULTS: Increased Ctr1 protein expression was observed for the most cisplatin-sensitive bladder cancer cell lines and MEFs. Cisplatin 69-78 solute carrier family 31 member 1 Homo sapiens 19-23 23879689-10 2013 Heat-induced increase in Ctr1 multimerisation with cisplatin was observed in Myc-tagged Ctr1 cells. Cisplatin 51-60 solute carrier family 31 member 1 Homo sapiens 25-29 23879689-10 2013 Heat-induced increase in Ctr1 multimerisation with cisplatin was observed in Myc-tagged Ctr1 cells. Cisplatin 51-60 solute carrier family 31 member 1 Homo sapiens 88-92 23879689-15 2013 Furthermore, Ctr1 protein profiles of bladder tumours, as well as other tumour types, may predict their response to cisplatin and overall efficacy of treatment. Cisplatin 116-125 solute carrier family 31 member 1 Homo sapiens 13-17 23642142-1 2013 Human copper transporter 1 (hCTR1) facilitates the cellular uptake of cisplatin, and the extracellular N-terminal domain has been proven to coordinate to platinum drugs. Cisplatin 70-79 solute carrier family 31 member 1 Homo sapiens 28-33 23642142-2 2013 It has been reported that the intracellular C-terminal motif is crucial for the function of hCTR1 in cisplatin influx. Cisplatin 101-110 solute carrier family 31 member 1 Homo sapiens 92-97 23642142-9 2013 This result indicates that hCTR1 can transfer cisplatin in the active form through a trans chelation process. Cisplatin 46-55 solute carrier family 31 member 1 Homo sapiens 27-32 23053666-0 2013 Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Cisplatin 48-57 solute carrier family 31 member 1 Homo sapiens 131-135 23482746-8 2013 Interestingly, copper-transporter-1, which is responsible for the intracellular accumulation of cisplatin, was not modulated by sex hormones and the effects of estrogen and progesterone were neither additive nor synergistic. Cisplatin 96-105 solute carrier family 31 member 1 Homo sapiens 15-35 26592130-1 2012 The cellular uptake of cisplatin and of other platinum-based drugs is mediated by the high-affinity copper transporter Ctr1. Cisplatin 23-32 solute carrier family 31 member 1 Homo sapiens 119-123 23010323-0 2012 Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. Cisplatin 38-47 solute carrier family 31 member 1 Homo sapiens 13-33 23010323-3 2012 Here, we describe a detailed investigation of the involvement of CTR1 in cisplatin uptake and its relevance for cisplatin resistance using a well characterised sensitive/cisplatin-resistant cell line pair: A2780 human ovarian carcinoma cell line and its cisplatin-resistant variant A2780cis. Cisplatin 73-82 solute carrier family 31 member 1 Homo sapiens 65-69 23010323-10 2012 Our results strongly suggest that CTR1 mediates cisplatin uptake in the cell lines studied. Cisplatin 48-57 solute carrier family 31 member 1 Homo sapiens 34-38 23010323-12 2012 Our findings imply that reduced CTR1 expression accounts for decreased cisplatin accumulation and represents one of the determinants of cisplatin resistance in A2780cis cell line. Cisplatin 71-80 solute carrier family 31 member 1 Homo sapiens 32-36 23010323-12 2012 Our findings imply that reduced CTR1 expression accounts for decreased cisplatin accumulation and represents one of the determinants of cisplatin resistance in A2780cis cell line. Cisplatin 136-145 solute carrier family 31 member 1 Homo sapiens 32-36 22914438-4 2012 In supporting this clinical study, using three pairs of cisplatin (cDDP)-resistant cell lines and two ovarian cancer cell lines derived from patients who had failed in platinum-based chemotherapy, we showed that cDDP resistance associated with reduced expression of the high-affinity copper transporter (hCtr1), which is also a cDDP transporter, can be preferentially resensitized by copper-lowering agents because of enhanced hCtr1 expression, as compared with their drug-sensitive counterparts. Cisplatin 56-65 solute carrier family 31 member 1 Homo sapiens 304-309 22914438-4 2012 In supporting this clinical study, using three pairs of cisplatin (cDDP)-resistant cell lines and two ovarian cancer cell lines derived from patients who had failed in platinum-based chemotherapy, we showed that cDDP resistance associated with reduced expression of the high-affinity copper transporter (hCtr1), which is also a cDDP transporter, can be preferentially resensitized by copper-lowering agents because of enhanced hCtr1 expression, as compared with their drug-sensitive counterparts. Cisplatin 56-65 solute carrier family 31 member 1 Homo sapiens 427-432 22725681-5 2012 Copper transporter protein 1 (CTR1) plays an essential role in cisplatin influx and is closely related to platinum resistance by influencing platinum uptake and accumulation. Cisplatin 63-72 solute carrier family 31 member 1 Homo sapiens 0-28 22725681-5 2012 Copper transporter protein 1 (CTR1) plays an essential role in cisplatin influx and is closely related to platinum resistance by influencing platinum uptake and accumulation. Cisplatin 63-72 solute carrier family 31 member 1 Homo sapiens 30-34 22962276-6 2012 Consistent with this notion is the finding that elevated hCtr1 expression was associated with favorable treatment outcomes in cisplatin-based cancer chemotherapy. Cisplatin 126-135 solute carrier family 31 member 1 Homo sapiens 57-62 22962276-7 2012 Moreover, cultured cell studies showed that elevated hCtr1 expression can be induced by depleting cellular copper levels, resulting in enhanced cisplatin uptake and its cell-killing activity. Cisplatin 144-153 solute carrier family 31 member 1 Homo sapiens 53-58 22552365-0 2012 Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1). Cisplatin 30-39 solute carrier family 31 member 1 Homo sapiens 68-88 22569840-1 2012 Human copper transporter 1 (hCTR1) is the major high affinity copper influx transporter in mammalian cells that also mediates uptake of the cancer chemotherapeutic agent cisplatin. Cisplatin 170-179 solute carrier family 31 member 1 Homo sapiens 6-26 22569840-1 2012 Human copper transporter 1 (hCTR1) is the major high affinity copper influx transporter in mammalian cells that also mediates uptake of the cancer chemotherapeutic agent cisplatin. Cisplatin 170-179 solute carrier family 31 member 1 Homo sapiens 28-33 22516052-0 2012 Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Cisplatin 67-76 solute carrier family 31 member 1 Homo sapiens 14-40 22516052-0 2012 Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Cisplatin 67-76 solute carrier family 31 member 1 Homo sapiens 42-46 22516052-4 2012 It has been identified that CTR1, copper transporter protein 1, plays an essential role in cisplatin uptake. Cisplatin 91-100 solute carrier family 31 member 1 Homo sapiens 28-32 22516052-10 2012 RESULT: CTR1 rs10981694 A>C polymorphism is associated with cisplatin induced severe toxicity in NSCLC patients. Cisplatin 63-72 solute carrier family 31 member 1 Homo sapiens 8-12 22516052-13 2012 CONCLUSION: NSCLC patients carrying C allele of CTR1 rs10981694 presented more sensitivity to ototoxicity after cisplatin treatment. Cisplatin 112-121 solute carrier family 31 member 1 Homo sapiens 48-52 22516052-14 2012 CTR1 plays an essential role in cisplatin toxicity and could be considered as a predictor for pretreatment evaluation in lung cancer patients. Cisplatin 32-41 solute carrier family 31 member 1 Homo sapiens 0-4 22552365-0 2012 Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1). Cisplatin 30-39 solute carrier family 31 member 1 Homo sapiens 90-95 22552365-3 2012 To study the effects of several metal-binding residues/motifs of hCTR1 on the transport of both Cu(+) and cisplatin, we have constructed Hela cells that stably express a series of hCTR1 variant proteins including H22-24A, NHA, C189S, hCTR1DeltaC, H139R and Y156A, and compared their abilities to regulate the accumulation and cytotoxicity of these metal compounds. Cisplatin 106-115 solute carrier family 31 member 1 Homo sapiens 65-70 22552365-6 2012 The cells expressing hCTR1 variants of H139R and Y156A exhibit lower capacities towards accumulation of copper but not cisplatin. Cisplatin 119-128 solute carrier family 31 member 1 Homo sapiens 21-26 22552365-7 2012 Significantly, cells with the C189S variant partially retained the ability of the wild-type hCTR1 protein to accumulate both copper and cisplatin, while for cells expressing the C-terminus truncated variant of hCTR1 (hCTR1DeltaC) this ability was absolutely abolished, suggesting that this motif is crucial for the function of the transporter. Cisplatin 136-145 solute carrier family 31 member 1 Homo sapiens 92-97 21868517-2 2011 One carrier involved in the transport of CS into the cell is the copper transporter CTR1. Cisplatin 41-43 solute carrier family 31 member 1 Homo sapiens 84-88 24278698-4 2012 Several transporters, which are expressed on the cell membranes, have been associated with cisplatin transport across the plasma membrane and across the cell: the copper transporter 1 (Ctr1), the copper transporter 2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B, the organic cation transporter 2 (OCT2), and the multidrug extrusion transporter 1 (MATE1). Cisplatin 91-100 solute carrier family 31 member 1 Homo sapiens 163-183 24278698-4 2012 Several transporters, which are expressed on the cell membranes, have been associated with cisplatin transport across the plasma membrane and across the cell: the copper transporter 1 (Ctr1), the copper transporter 2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B, the organic cation transporter 2 (OCT2), and the multidrug extrusion transporter 1 (MATE1). Cisplatin 91-100 solute carrier family 31 member 1 Homo sapiens 185-189 21868517-4 2011 The proteasome inhibitor bortezomib (Bort) has been reported to block CS-induced down-regulation of CTR1 so that in the presence of Bort, the cellular uptake of CS may be increased. Cisplatin 70-72 solute carrier family 31 member 1 Homo sapiens 100-104 21981264-4 2011 The major Cu(I) influx transporter Ctr1 has been found to mediate transport of cisplatin and its analogues. Cisplatin 79-88 solute carrier family 31 member 1 Homo sapiens 35-39 21868517-4 2011 The proteasome inhibitor bortezomib (Bort) has been reported to block CS-induced down-regulation of CTR1 so that in the presence of Bort, the cellular uptake of CS may be increased. Cisplatin 161-163 solute carrier family 31 member 1 Homo sapiens 100-104 21868517-3 2011 However, CS is found to trigger the down-regulation of CTR1 and its proteasomal degradation. Cisplatin 9-11 solute carrier family 31 member 1 Homo sapiens 55-59 21177414-7 2011 Reduced influx, accompanied by the reduction of protein level of copper transporter 1, accounts for decreased intracellular cisplatin accumulation. Cisplatin 124-133 solute carrier family 31 member 1 Homo sapiens 65-85 21602128-0 2011 [Cisplatin induces drug resistance in human esophageal squamous carcinoma cell line EC109 by decreasing CTR1 protein expression]. Cisplatin 1-10 solute carrier family 31 member 1 Homo sapiens 104-108 21602128-7 2011 CONCLUSION: Cisplatin induces drug resistant phenotype by decreasing the protein level of CTR1, which controls cell accumulation and cytotoxic effect of cisplatin. Cisplatin 12-21 solute carrier family 31 member 1 Homo sapiens 90-94 21602128-7 2011 CONCLUSION: Cisplatin induces drug resistant phenotype by decreasing the protein level of CTR1, which controls cell accumulation and cytotoxic effect of cisplatin. Cisplatin 153-162 solute carrier family 31 member 1 Homo sapiens 90-94 21387471-0 2011 The effect of the extracellular domain of human copper transporter (hCTR1) on cisplatin activation. Cisplatin 78-87 solute carrier family 31 member 1 Homo sapiens 68-73 20451502-0 2010 The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Cisplatin 93-102 solute carrier family 31 member 1 Homo sapiens 40-60 20519567-0 2010 The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Cisplatin 137-146 solute carrier family 31 member 1 Homo sapiens 84-104 20519567-1 2010 Mammalian copper transporter 1 (CTR1) is a high-affinity copper influx transporter that also mediates the uptake of platinum-containing chemotherapeutic agents including cisplatin (cDDP). Cisplatin 170-179 solute carrier family 31 member 1 Homo sapiens 10-30 20519567-1 2010 Mammalian copper transporter 1 (CTR1) is a high-affinity copper influx transporter that also mediates the uptake of platinum-containing chemotherapeutic agents including cisplatin (cDDP). Cisplatin 170-179 solute carrier family 31 member 1 Homo sapiens 32-36 20194531-2 2010 Cisplatin (DDP) triggers the rapid degradation of CTR1 and thus limits its own accumulation. Cisplatin 0-9 solute carrier family 31 member 1 Homo sapiens 50-54 20541702-1 2010 Uptake of the anticancer drug cisplatin is mediated by the copper transporter CTR1 in cultured cells. Cisplatin 30-39 solute carrier family 31 member 1 Homo sapiens 78-82 20159940-3 2010 The major copper influx transporter, copper transporter 1 (CTR1), has now been shown to control the tumor cell accumulation and cytotoxic effect of cisplatin, carboplatin, and oxaliplatin. Cisplatin 148-157 solute carrier family 31 member 1 Homo sapiens 59-63 20159940-4 2010 There is a good correlation between change in CTR1 expression and acquired cisplatin resistance among ovarian cancer cell lines, and genetic knockout of CTR1 renders cells resistant to cisplatin in vivo. Cisplatin 75-84 solute carrier family 31 member 1 Homo sapiens 46-50 20159940-4 2010 There is a good correlation between change in CTR1 expression and acquired cisplatin resistance among ovarian cancer cell lines, and genetic knockout of CTR1 renders cells resistant to cisplatin in vivo. Cisplatin 185-194 solute carrier family 31 member 1 Homo sapiens 153-157 20159940-6 2010 Copper and cisplatin both trigger the down-regulation of CTR1 via a process that involves ubiquitination and proteosomal degradation and requires the copper chaperone antioxidant protein 1 (ATOX1). Cisplatin 11-20 solute carrier family 31 member 1 Homo sapiens 57-61 20631178-3 2010 A CTR1 substrate, copper sulfate, decreased the uptake and cytotoxicity of cisplatin in HEI-OC1, a cell line that expresses many molecular markers reminiscent of OHCs. Cisplatin 75-84 solute carrier family 31 member 1 Homo sapiens 2-6 20159940-7 2010 The cisplatin-induced degradation of CTR1 can be blocked with the proteosome inhibitor bortezomib, and this increases the cellular uptake and the cytotoxicity of cisplatin in a synergistic manner. Cisplatin 4-13 solute carrier family 31 member 1 Homo sapiens 37-41 20194531-4 2010 Changes in CTR1 and CTR2 mRNA and protein levels in human ovarian carcinoma 2008 cells and ATOX1(+/+) and ATOX1(-/-) mouse embryo fibroblasts in response to exposure to DDP and copper were measured by quantitative reverse transcriptase-polymerase chain reaction, Western blot analysis, and deconvolution microscopy. Cisplatin 169-172 solute carrier family 31 member 1 Homo sapiens 11-15 20159940-7 2010 The cisplatin-induced degradation of CTR1 can be blocked with the proteosome inhibitor bortezomib, and this increases the cellular uptake and the cytotoxicity of cisplatin in a synergistic manner. Cisplatin 162-171 solute carrier family 31 member 1 Homo sapiens 37-41 19529937-8 2010 Knockdown of hCtr1 (the human copper transporter 1) by siRNA abrogated this inhibition in cisplatin uptake. Cisplatin 90-99 solute carrier family 31 member 1 Homo sapiens 13-18 19529937-8 2010 Knockdown of hCtr1 (the human copper transporter 1) by siRNA abrogated this inhibition in cisplatin uptake. Cisplatin 90-99 solute carrier family 31 member 1 Homo sapiens 30-50 19529937-9 2010 CONCLUSION: The results demonstrate that co-exposure of tumor cells to emodin or DRB with cisplatin inhibits platinum drug uptake by impacting the hCtr1 transporter and, thereby, reduce the cytotoxicity of cisplatin. Cisplatin 90-99 solute carrier family 31 member 1 Homo sapiens 147-152 19529937-9 2010 CONCLUSION: The results demonstrate that co-exposure of tumor cells to emodin or DRB with cisplatin inhibits platinum drug uptake by impacting the hCtr1 transporter and, thereby, reduce the cytotoxicity of cisplatin. Cisplatin 206-215 solute carrier family 31 member 1 Homo sapiens 147-152 19570948-2 2009 hCtr1 is involved in the transport of platinum-based antitumor agents such as cisplatin (CDDP); however, the mechanisms that regulate hCtr1-mediated transport of these agents have not been well elucidated. Cisplatin 78-87 solute carrier family 31 member 1 Homo sapiens 0-5 19669174-7 2009 Time-dependent 2D [(1)H,(15)N] heteronuclear single quantum coherence NMR spectra indicate the reaction of cisplatin with hCtr1-N20 is a stepwise process. Cisplatin 107-116 solute carrier family 31 member 1 Homo sapiens 122-127 21072377-3 2010 The copper transport protein Ctr1 is responsible for high affinity copper uptake but has also been implicated in the transport of cisplatin into cells. Cisplatin 130-139 solute carrier family 31 member 1 Homo sapiens 29-33 21072377-5 2010 In these studies, we use liquid chromatography and mass spectrometry to compare the binding interactions between cisplatin, carboplatin and oxaliplatin with synthetic peptides corresponding to hCtr1 Mets motifs. Cisplatin 113-122 solute carrier family 31 member 1 Homo sapiens 193-198 21274436-3 2010 Both Cu transporters CTR1 and CTR2 influence the uptake and cytotoxicity of cisplatin. Cisplatin 76-85 solute carrier family 31 member 1 Homo sapiens 21-25 19075668-11 2008 In addition, the copper uptake transporter CTR1 has also been reported to play a role in CDDP sensitivity. Cisplatin 89-93 solute carrier family 31 member 1 Homo sapiens 43-47 19034536-4 2009 In the context of the Met-rich Cu(I) pump Ctr1 as a significant entry point for cisplatin into mammalian cells, the present work confirms the ability of Met-rich sites in proteins to remove all ligands from cisplatin. Cisplatin 80-89 solute carrier family 31 member 1 Homo sapiens 42-46 19034536-4 2009 In the context of the Met-rich Cu(I) pump Ctr1 as a significant entry point for cisplatin into mammalian cells, the present work confirms the ability of Met-rich sites in proteins to remove all ligands from cisplatin. Cisplatin 207-216 solute carrier family 31 member 1 Homo sapiens 42-46 19134212-11 2009 The expression of CTR1, which is associated with cisplatin (DDP)-resistance, was significantly decreased in p75NTR+ cells. Cisplatin 49-58 solute carrier family 31 member 1 Homo sapiens 18-22 18998134-2 2009 Expression of the human copper transporter 1 (hCtr1) is thought to result in increased sensitivity to cisplatin, whereas expression of ATP7A and ATP7B are thought to be involved in resistance to cisplatin either by sequestering drug away from its targets (ATP7A) or by exporting the drug from the cell (ATP7B). Cisplatin 102-111 solute carrier family 31 member 1 Homo sapiens 24-44 18998134-2 2009 Expression of the human copper transporter 1 (hCtr1) is thought to result in increased sensitivity to cisplatin, whereas expression of ATP7A and ATP7B are thought to be involved in resistance to cisplatin either by sequestering drug away from its targets (ATP7A) or by exporting the drug from the cell (ATP7B). Cisplatin 102-111 solute carrier family 31 member 1 Homo sapiens 46-51 19147760-0 2009 Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Cisplatin 21-30 solute carrier family 31 member 1 Homo sapiens 120-140 19147760-2 2009 However, the accumulation of cisplatin in human ovarian carcinoma cells is limited by the fact that cisplatin triggers the down-regulation and proteasomal degradation of CTR1, thereby limiting its own uptake. Cisplatin 29-38 solute carrier family 31 member 1 Homo sapiens 170-174 19147760-2 2009 However, the accumulation of cisplatin in human ovarian carcinoma cells is limited by the fact that cisplatin triggers the down-regulation and proteasomal degradation of CTR1, thereby limiting its own uptake. Cisplatin 100-109 solute carrier family 31 member 1 Homo sapiens 170-174 19147760-6 2009 RESULTS: Bortezomib blocked the cisplatin-induced down-regulation of hCTR1 in a concentration-dependent manner and increased cisplatin uptake 1.6- to 2.4-fold. Cisplatin 32-41 solute carrier family 31 member 1 Homo sapiens 69-74 19147760-14 2009 CONCLUSIONS: Proteasomal inhibition prevented cisplatin-induced down-regulation of hCTR1 in ovarian cancer cells and enhanced drug uptake and cell killing in a synergistic manner. Cisplatin 46-55 solute carrier family 31 member 1 Homo sapiens 83-88 18523133-0 2008 Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Cisplatin 61-70 solute carrier family 31 member 1 Homo sapiens 119-124 17108132-0 2006 The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cisplatin 76-85 solute carrier family 31 member 1 Homo sapiens 45-65 17318448-4 2007 Ctr1, the major copper influx transporter, has been convincingly demonstrated to transport cisplatin and its analogues, carboplatin, and oxaliplatin. Cisplatin 91-100 solute carrier family 31 member 1 Homo sapiens 0-4 17695505-0 2007 Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Cisplatin 101-110 solute carrier family 31 member 1 Homo sapiens 63-67 17097621-9 2007 The results highlight the relevance of CTR1 for cisplatin sensitivity as there is a clear relationship between lower CTR1 expression, intracellular concentration, DNA platination and cytotoxicity of cisplatin in both resistant cell lines. Cisplatin 48-57 solute carrier family 31 member 1 Homo sapiens 39-43 17097621-9 2007 The results highlight the relevance of CTR1 for cisplatin sensitivity as there is a clear relationship between lower CTR1 expression, intracellular concentration, DNA platination and cytotoxicity of cisplatin in both resistant cell lines. Cisplatin 48-57 solute carrier family 31 member 1 Homo sapiens 117-121 17097621-9 2007 The results highlight the relevance of CTR1 for cisplatin sensitivity as there is a clear relationship between lower CTR1 expression, intracellular concentration, DNA platination and cytotoxicity of cisplatin in both resistant cell lines. Cisplatin 199-208 solute carrier family 31 member 1 Homo sapiens 39-43 17097621-9 2007 The results highlight the relevance of CTR1 for cisplatin sensitivity as there is a clear relationship between lower CTR1 expression, intracellular concentration, DNA platination and cytotoxicity of cisplatin in both resistant cell lines. Cisplatin 199-208 solute carrier family 31 member 1 Homo sapiens 117-121 17108132-1 2006 The human copper transporter 1 (hCTR1), the major transporter responsible for copper influx, mediates one component of the cellular accumulation of cisplatin (DDP). Cisplatin 148-157 solute carrier family 31 member 1 Homo sapiens 10-30 17108132-1 2006 The human copper transporter 1 (hCTR1), the major transporter responsible for copper influx, mediates one component of the cellular accumulation of cisplatin (DDP). Cisplatin 148-157 solute carrier family 31 member 1 Homo sapiens 32-37 16501047-1 2006 Human CTR1 is a high-affinity copper transporter that also mediates the uptake of the anticancer drug cisplatin by largely unknown transport mechanisms. Cisplatin 102-111 solute carrier family 31 member 1 Homo sapiens 6-10 16709730-1 2006 The major copper influx transporter, copper transporter 1 (hCTR1), controls the cellular accumulation of cisplatin in mammalian cells. Cisplatin 105-114 solute carrier family 31 member 1 Homo sapiens 4-57 16709730-1 2006 The major copper influx transporter, copper transporter 1 (hCTR1), controls the cellular accumulation of cisplatin in mammalian cells. Cisplatin 105-114 solute carrier family 31 member 1 Homo sapiens 59-64 15607932-1 2005 Recent studies have demonstrated that the major Cu influx transporter CTR1 regulates tumor cell uptake of cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (L-OHP), and that the two Cu efflux transporters ATP7A and ATP7B regulate the efflux of these drugs. Cisplatin 106-115 solute carrier family 31 member 1 Homo sapiens 70-74 15326162-0 2004 Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters. Cisplatin 0-9 solute carrier family 31 member 1 Homo sapiens 55-59 15634647-0 2004 Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Cisplatin 93-102 solute carrier family 31 member 1 Homo sapiens 33-37 15634647-0 2004 Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Cisplatin 117-126 solute carrier family 31 member 1 Homo sapiens 33-37 15634647-1 2004 Recent studies have shown that the mammalian high-affinity copper transporter encoded by Ctr1 is involved in the uptake of cisplatin. Cisplatin 123-132 solute carrier family 31 member 1 Homo sapiens 89-93 15634647-2 2004 However, the roles of hCtr1 in cisplatin-sensitive and cisplatin-resistant mammalian cells have not been investigated. Cisplatin 31-40 solute carrier family 31 member 1 Homo sapiens 22-27 15634647-3 2004 Here, we show that, of five cisplatin-resistant cell lines, only one (SR2) exhibited substantial reduction in hCtr1 expression as compared with that in its sensitive line small cell lung cancers (SCLC), whereas copper efflux transporters ATP7A and ATP7B were not significantly altered. Cisplatin 28-37 solute carrier family 31 member 1 Homo sapiens 110-115 15634647-5 2004 Transfection of expression hemagglutinin-tagged hCtr1 cDNA into SCLC and SR2 cells enhanced the uptake of copper, cisplatin, carboplatin, and oxaliplatin, suggesting that hCtr1 transporter can transport these platinum-based drugs. Cisplatin 114-123 solute carrier family 31 member 1 Homo sapiens 48-53 15634647-6 2004 Whereas increased sensitivities to all these platinum drugs were observed in hCtr1-transfected SCLC cells, increased sensitivities to cisplatin and carboplatin but not to oxaliplatin were observed in hCtr1-transfected SR2 cells. Cisplatin 134-143 solute carrier family 31 member 1 Homo sapiens 200-205 15634647-9 2004 These results collectively show the importance of hCtr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant variants. Cisplatin 111-120 solute carrier family 31 member 1 Homo sapiens 50-55 15634647-9 2004 These results collectively show the importance of hCtr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant variants. Cisplatin 135-144 solute carrier family 31 member 1 Homo sapiens 50-55 15326162-3 2004 The human high affinity copper importer, hCtr1, and its yeast and murine orthologues have been shown to mediate the uptake of cisplatin. Cisplatin 126-135 solute carrier family 31 member 1 Homo sapiens 41-46 15326162-5 2004 In this study we further examined the link between cisplatin and hCtr1 by examining whether cisplatin can also stimulate the endocytosis and degradation of hCtr1. Cisplatin 92-101 solute carrier family 31 member 1 Homo sapiens 156-161 15326162-7 2004 Unexpectedly, cisplatin treatment of a cell line expressing hCtr1 revealed the time- and concentration-dependent appearance of a stable hCtr1 multimeric complex, consistent with a homotrimer, which was not observed following copper treatment of these same cells. Cisplatin 14-23 solute carrier family 31 member 1 Homo sapiens 60-65 15326162-7 2004 Unexpectedly, cisplatin treatment of a cell line expressing hCtr1 revealed the time- and concentration-dependent appearance of a stable hCtr1 multimeric complex, consistent with a homotrimer, which was not observed following copper treatment of these same cells. Cisplatin 14-23 solute carrier family 31 member 1 Homo sapiens 136-141 15326162-8 2004 Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form crosslinks between hCtr1 polypeptides. Cisplatin 174-183 solute carrier family 31 member 1 Homo sapiens 106-111 15326162-8 2004 Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form crosslinks between hCtr1 polypeptides. Cisplatin 174-183 solute carrier family 31 member 1 Homo sapiens 156-161 15326162-8 2004 Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form crosslinks between hCtr1 polypeptides. Cisplatin 174-183 solute carrier family 31 member 1 Homo sapiens 156-161 15326162-8 2004 Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form crosslinks between hCtr1 polypeptides. Cisplatin 222-231 solute carrier family 31 member 1 Homo sapiens 106-111 15326162-8 2004 Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form crosslinks between hCtr1 polypeptides. Cisplatin 222-231 solute carrier family 31 member 1 Homo sapiens 156-161 15326162-8 2004 Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form crosslinks between hCtr1 polypeptides. Cisplatin 222-231 solute carrier family 31 member 1 Homo sapiens 156-161 15326162-9 2004 Treatment with the metal chelator dimethyldithiocarbamate disassembled the hCtr1 multimer following cisplatin exposure, suggesting that platinum was an integral component of this complex. Cisplatin 100-109 solute carrier family 31 member 1 Homo sapiens 75-80 15326162-10 2004 These studies provide the first evidence for a direct interaction between cisplatin and the hCtr1 protein and establish that cisplatin and copper have distinct biochemical consequences on this transporter. Cisplatin 74-83 solute carrier family 31 member 1 Homo sapiens 92-97 15326162-10 2004 These studies provide the first evidence for a direct interaction between cisplatin and the hCtr1 protein and establish that cisplatin and copper have distinct biochemical consequences on this transporter. Cisplatin 125-134 solute carrier family 31 member 1 Homo sapiens 92-97 15229296-1 2004 Cells selected for resistance to cisplatin are often cross-resistant to copper and vice versa, and the major copper influx transporter copper transport protein 1 (CTR1) has been shown to regulate the uptake of cisplatin, carboplatin, and oxaliplatin in yeast. Cisplatin 33-42 solute carrier family 31 member 1 Homo sapiens 163-167 15475465-0 2004 Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Cisplatin 0-9 solute carrier family 31 member 1 Homo sapiens 60-65 15229296-1 2004 Cells selected for resistance to cisplatin are often cross-resistant to copper and vice versa, and the major copper influx transporter copper transport protein 1 (CTR1) has been shown to regulate the uptake of cisplatin, carboplatin, and oxaliplatin in yeast. Cisplatin 210-219 solute carrier family 31 member 1 Homo sapiens 163-167 15229296-4 2004 The A2780/hCTR1 cells accumulated 46% more platinum after a 1-h exposure to 2 microM cisplatin, and 55% more after a 24 h exposure, than the control A2780/empty vector cells. Cisplatin 85-94 solute carrier family 31 member 1 Homo sapiens 10-15 15229296-5 2004 The initial uptake of cisplatin was 81% higher in the A2780/hCTR1 cells when measured at 5 min. Cisplatin 22-31 solute carrier family 31 member 1 Homo sapiens 60-65 15229296-6 2004 Thus, increased expression of hCTR1 had a substantially larger effect on the cellular pharmacology of copper than cisplatin. Cisplatin 114-123 solute carrier family 31 member 1 Homo sapiens 30-35 15229296-8 2004 Thus, although increased expression of hCTR1 mediates greater cellular accumulation of copper and cisplatin, hCTR1 delivers these compounds into intracellular compartments from which they do not have ready access to their key cytotoxic targets. Cisplatin 98-107 solute carrier family 31 member 1 Homo sapiens 39-44 15194000-0 2004 Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Cisplatin 25-34 solute carrier family 31 member 1 Homo sapiens 93-97 15194000-0 2004 Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Cisplatin 120-129 solute carrier family 31 member 1 Homo sapiens 93-97 15194000-4 2004 In an attempt to examine the role of human copper transporter 1 (CTR1) in cisplatin accumulation by human cells, we selected the well characterized A431 cell line and the resistant variant A431/Pt. Cisplatin 74-83 solute carrier family 31 member 1 Homo sapiens 43-63 15194000-4 2004 In an attempt to examine the role of human copper transporter 1 (CTR1) in cisplatin accumulation by human cells, we selected the well characterized A431 cell line and the resistant variant A431/Pt. Cisplatin 74-83 solute carrier family 31 member 1 Homo sapiens 65-69 15194000-9 2004 In conclusion, our results indicate that the overexpression of a functional CTR1 in a human cell line characterized by impaired cisplatin uptake fails (a) to restore cellular drug accumulation to the level of the parental cell line and (b) to modulate cisplatin sensitivity. Cisplatin 128-137 solute carrier family 31 member 1 Homo sapiens 76-80 15194000-9 2004 In conclusion, our results indicate that the overexpression of a functional CTR1 in a human cell line characterized by impaired cisplatin uptake fails (a) to restore cellular drug accumulation to the level of the parental cell line and (b) to modulate cisplatin sensitivity. Cisplatin 252-261 solute carrier family 31 member 1 Homo sapiens 76-80 34521054-0 2021 ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. Cisplatin 32-41 solute carrier family 31 member 1 Homo sapiens 126-133 12370430-9 2002 The link between Ctr1p and cisplatin transport may explain some cases of cisplatin resistance in humans and suggests ways of modulating sensitivity and toxicity to this important anticancer drug. Cisplatin 27-36 solute carrier family 31 member 1 Homo sapiens 17-22 12370430-9 2002 The link between Ctr1p and cisplatin transport may explain some cases of cisplatin resistance in humans and suggests ways of modulating sensitivity and toxicity to this important anticancer drug. Cisplatin 73-82 solute carrier family 31 member 1 Homo sapiens 17-22 34275285-6 2021 Moreover, free cisplatin liberated from dead cells infected neighboring tumor cells quickly via ONOO--mediated up-regulated copper transporter 1, further amplifying chemotherapeutic efficacy. Cisplatin 15-24 solute carrier family 31 member 1 Homo sapiens 124-144 35573297-4 2022 Further evidence has shown that certain transporters can mediate cisplatin influx into the inner ear cells including organic cation transporter 2 (OCT2) and the copper transporter Ctr1. Cisplatin 65-74 solute carrier family 31 member 1 Homo sapiens 180-184